Modelling the Epidemiological Impact of Different Adult Pneumococcal Vaccination Strategies in the United Kingdom.

ABSTRACT:

Introduction

Pneumococcal conjugate vaccines (PCVs) were first introduced in the paediatric United Kingdom (UK) immunisation programme in 2006 which led to significant declines in invasive pneumococcal disease (IPD) caused by targeted serotypes. Although paediatric PCVs provide some indirect protection to adults, a significant IPD burden remains in older adults. Here, we compared three adult (65+ years-old) and risk group (2-64-year-old) vaccination scenarios, namely a continuation of the status quo with PPSV23 vaccination, using the recently licensed-in-adults PCV20, or using the new adult-focused 21-valent PCV, V116.

Methods

A population-level compartmental dynamic transmission model (DTM) was adapted to the UK setting. The model described Streptococcus pneumoniae carriage

SUBMITTER: Oidtman RJ 

PROVIDER: S-EPMC11933510 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature